NASDAQ:FTH Sensei Biotherapeutics (FTH) Stock Price, News & Analysis $40.05 0.00 (0.00%) As of 09/4/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Sensei Biotherapeutics Stock (NASDAQ:FTH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sensei Biotherapeutics alerts:Sign Up Key Stats Today's Range$38.35▼$41.1650-Day Range$22.92▼$40.0552-Week Range$7.45▼$41.16Volume274,991 shsAverage Volume299,123 shsMarket Capitalization$1.03 billionP/E RatioN/ADividend YieldN/APrice Target$55.00Consensus RatingModerate Buy Company Overview Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies. The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways. In addition to these clinical-stage candidates, Sensei is advancing preclinical projects against novel innate immune checkpoints and exploring combination regimens to broaden therapeutic impact. Founded in 2018 and headquartered in Cambridge, Massachusetts, Sensei Biotherapeutics operates across the United States and collaborates with academic and industry partners to accelerate research and development. The company’s leadership team brings extensive experience in antibody therapeutics, translational research and clinical development, supporting its mission to bring innovative immunotherapies through clinical trials and deliver new treatment options for patients worldwide. AI Generated. May Contain Errors. Read More Sensei Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScoreFTH MarketRank™: Sensei Biotherapeutics scored higher than 82% of companies evaluated by MarketBeat, and ranked 109th out of 910 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingSensei Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 1 strong buy rating, 10 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialSensei Biotherapeutics has a consensus price target of $55.00, representing about 37.3% upside from its current price of $40.05.Amount of Analyst CoverageSensei Biotherapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Sensei Biotherapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sensei Biotherapeutics are expected to grow in the coming year, from ($13.18) to ($3.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sensei Biotherapeutics is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sensei Biotherapeutics is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSensei Biotherapeutics has a P/B Ratio of 2.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.44% of the float of Sensei Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverSensei Biotherapeutics has a short interest ratio ("days to cover") of 2.75, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sensei Biotherapeutics has recently increased by 1.42%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSensei Biotherapeutics does not currently pay a dividend.Dividend GrowthSensei Biotherapeutics does not have a long track record of dividend growth. News and Social Media2.3 / 5News Sentiment0.63 News SentimentSensei Biotherapeutics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Sensei Biotherapeutics this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for FTH on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Sensei Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.9 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of Sensei Biotherapeutics in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $1,188,822.00 in company stock, which represents 0.1149% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Sensei Biotherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,188,822.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders7.00% of the stock of Sensei Biotherapeutics is held by insiders.Percentage Held by Institutions10.50% of the stock of Sensei Biotherapeutics is held by institutions.Read more about Sensei Biotherapeutics' insider trading history. Receive FTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sensei Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FTH Stock News HeadlinesFaeth Therapeutics to Participate in Upcoming September Investor ConferencesSeptember 1, 2026 | businesswire.comFaeth Therapeutics Announces FDA Grant of Fast Track Designation for PIKTOR Plus Paclitaxel in Biomarker-Selected Advanced Endometrial CancerAugust 17, 2026 | businesswire.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.September 7 at 1:00 AM | Banyan Hill Publishing (Ad)Faeth Therapeutics Strengthens Executive Team with Senior Leadership AppointmentsAugust 14, 2026 | businesswire.comFaeth Therapeutics: PI3K Pathway Inhibitor With Key Data Catalyst In Play IntriguesAugust 11, 2026 | seekingalpha.comFaeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 7, 2026 | businesswire.comFaeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational UpdatesAugust 4, 2026 | businesswire.comThis Faeth Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For FridayJuly 31, 2026 | benzinga.comSee More Headlines FTH Stock Analysis - Frequently Asked Questions How have FTH shares performed this year? Sensei Biotherapeutics' stock was trading at $16.65 on June 17, 2026. Since then, FTH shares have increased by 140.5% and is now trading at $40.05. How were Sensei Biotherapeutics' earnings last quarter? Sensei Biotherapeutics, Inc. (NASDAQ:FTH) announced its quarterly earnings data on Tuesday, August, 4th. The company reported ($2.84) EPS for the quarter, beating analysts' consensus estimates of ($5.05) by $2.21. When did Sensei Biotherapeutics' stock split? Shares of Sensei Biotherapeutics reverse split before market open on Tuesday, June 17th 2025.The 1-20 reverse split was announced on Friday, June 13th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 16th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Sensei Biotherapeutics' major shareholders? Top institutional shareholders of Sensei Biotherapeutics include Alyeska Investment Group L.P. (0.56%) and Citadel Advisors LLC (0.05%). Insiders that own company stock include Anand Kiran Parikh, Millennium Management Llc, James Peyer and John Celebi. View institutional ownership trends. How do I buy shares of Sensei Biotherapeutics? Shares of FTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sensei Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sensei Biotherapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Tesla (TSLA), Advanced Micro Devices (AMD), Plug Power (PLUG), PayPal (PYPL) and Walt Disney (DIS). Company Calendar Last Earnings8/04/2026Today9/07/202612th Annual Cantor Fitzgerald Global Healthcare Conference9/10/2026Morgan Stanley 24th Annual Global Healthcare Conference9/14/2026KOL event10/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 FTH's financial health is in the Green zone, according to TradeSmith. FTH has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:FTH Previous SymbolNASDAQ:SNSE CIK1829802 Webwww.senseibio.com Phone240-243-8000FaxN/AEmployees40Year Founded1999Price Target and Rating Average Price Target for Sensei Biotherapeutics$55.00 High Price Target$60.00 Low Price Target$50.00 Potential Upside/Downside+37.3%Consensus RatingModerate Buy Rating Score (0-4)2.85 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($141.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.08 million Net MarginsN/A Pretax MarginN/A Return on Equity-1,012.17% Return on Assets-175.69% Debt Debt-to-Equity RatioN/A Current Ratio19.69 Quick Ratio19.69 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$14.74 per share Price / Book2.72Miscellaneous Outstanding Shares25,840,000Free Float24,031,000Market Cap$1.03 billion OptionableNot Optionable Beta-0.28 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:FTH) was last updated on 9/7/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sensei Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sensei Biotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
